Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings while missing slightly on the top-line: net loss of $26.8M vs. $29.0M expected, with EPS of -$0.22 vs. -$0.26 expected. Grant revenue of $81K fell short of the $92K consensus. The company reported a significant cash position of $237M, extending its runway into late 2027, as it prepares to initiate its first Phase 3 study for VMT-α-NET by year-end 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Perspective Therapeutics(CATX) the Revenue is 81 K (-72.07%), Miss estimate;the EBIT is -29.26 M (-21.71%), Beat estimate;the EPS is -0.22 (+24.14%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B72.07%
0.00B68.12%
-0.00B3.95%
EBITExceed expectations
-0.03B21.71%
-0.03B26.89%
+0.00B5.18%
EPSExceed expectations
-0.2224.14%
-0.256611.51%
+0.036612.63%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf